Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir-Reference-Cited by-同舟云学术

Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir

Published:2023-04 Issue:4 Volume:29 Page:543.e5-543.e9
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Martin-Blondel Guillaume,Marcelin Anne-Geneviève,Soulié Cathia,Kaisaridi Sofia,Lusivika-Nzinga Clovis,Zafilaza Karen,Dorival Céline,Nailler Laura,Boston Anaïs,Ronchetti Anne-Marie,Melenotte Cléa,Cabié André,Choquet Christophe,Trinh-Duc Albert,Lacombe Karine,Gaube Géraldine,Coustillères François,Pourcher Valérie,Martellosio Jean-Philippe,Peiffer-Smadja Nathan,Chauveau Marie,Housset Pierre,Piroth Lionel,Devaux Mathilde,Pialoux Gilles,Martin Aurélie,Dubee Vincent,Frey Jérôme,Le Bot Audrey,Cazanave Charles,Petua Philippe,Liblau Roland,Carrat Fabrice,Yordanov Youri

Funder

Agence Nationale de Recherches sur le Sida et les Hépatites Virales

French Government Ministry of Education Research and Technology

Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation

Ministère des Solidarités et de la Santé

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference17 articles.

1. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19;Gupta;JAMA,2022

2. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19;Hammond;N Engl J Med,2022